CHIVID: A Rapid Deployment of Community and Home Isolation During COVID-19 Pandemics.

Background: CHIVID is a telemedicine solution developed under tight time constraints that assists Thai healthcare practitioners in monitoring non-severe COVID-19 patients in isolation programs during crises. It assesses patient health and notifies healthcare practitioners of high-risk scenarios through a chatbot. The system was designed to integrate with the famous Thai messaging app LINE, reducing development time and enhancing user-friendliness, and the system allowed patients to upload a pulse oximeter image automatically processed by the PACMAN function to extract oxygen saturation and heart rate values to reduce patient input errors.

SARIMA Model Forecasting Performance of the COVID-19 Daily Statistics in Thailand during the Omicron Variant Epidemic.

This study aims to identify and evaluate a robust and replicable public health predictive model that can be applied to the COVID-19 time-series dataset, and to compare the model performance after performing the 7-day, 14-day, and 28-day forecast interval. The seasonal autoregressive integrated moving average (SARIMA) model was developed and validated using a Thailand COVID-19 open dataset from 1 December 2021 to 30 April 2022, during the Omicron variant outbreak. The SARIMA model with a non-statistically significant p-value of the Ljung-Box test, the lowest AIC, and the lowest RMSE was selected from the top five candidates for model validation.

Symptom-based data preprocessing for the detection of disease outbreak.

Early warning systems for outbreak detection is a challenge topic for researchers in the epidemiology and biomedical informatics fields. We are proposing a new method for detecting disease epidemics using a symptom-based approach. The data was collected from developed mobile applications which include users' demographic information and a list of chief complaint symptoms.

A pharmacokinetic model of lopinavir in combination with ritonavir in human.

Ritonavir-boosted lopinavir (LPV/r) has been recommended as an alternative regimen for HIV-naive patients who cannot tolerate nevirapine (NVP) and/or efavirenz (EFV). Although combinations of ritonavir and lopinavir have shown higher plasma concentration level of LPV in clinical settings, dosage adjustment is still required to maintain an adequate therapeutic efficacy and reduce side effects. A compartmental pharmacokinetic (PK) model of LPV/r was developed, including a mechanistic description of competitive inhibition.

Compartmental pharmacokinetic modeling of lopinavir in humans.

Background: Lopinavir is a highly potent protease inhibitors commonly used in treatment of HIV infection. The drug has a very low bioavailability due to a rapid metabolism by cytochrome P450 3A (CYP3A) isoenzyme. We aimed to develop a biologically relevant pharmacokinetic model of lopinavir with a description of a CYP3A4-mediated first pass metabolism and enterohepatic circulation (EHC).